RxDoctor Payments Data

Stephen Schiff, MD

Urology · Putnam, CTNPI 1598723124

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,285 of the $12,880 with a category attached, or 79.9%. Astellas Pharma US Inc accounts for 85.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $7,103 and has fallen 90.2% since, to $698 in 2025.

$12,880in general payments, 2019–2025

Across 87 payments — averaging $148.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$11K
  • Coloplast$341
  • Sumitomo Pharma America, Inc.$280
  • Procept Biorobotics Corporation$182
  • Teleflex LLC$179
  • Telix Pharmaceuticals$150
  • plus $688 from 12 others

What the payments were for

  • Speaking & faculty fees$10,28580%
  • Travel & lodging$2912%
  • Food & beverage$1,94715%
  • Education$3573%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,880 in reported general payments places this provider in the 85th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$78,742
Medicare patients
214
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron128$130,111
OrgovyxRelugolix32$86,982
MyrbetriqMirabegron87$77,082
Silodosin129$14,708
Tamsulosin Hcl433$6,559
Tolterodine Tartrate ErTolterodine Tartrate57$6,116
Methenamine Hippurate47$3,387
Oxybutynin Chloride ErOxybutynin Chloride121$3,028
Solifenacin Succinate70$3,006
Alfuzosin Hcl ErAlfuzosin Hcl134$2,953
Finasteride235$2,878
Fesoterodine Fumarate ErFesoterodine Fumarate13$1,879
Tadalafil17$749
Estradiol16$635
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst88$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$280$217,093160 claims
Astellas Pharma US IncMyrbetriq$11,060$77,08287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 urology providers in Connecticut.

Other urology in Putnam

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →